GB2596491B - Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients - Google Patents

Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients Download PDF

Info

Publication number
GB2596491B
GB2596491B GB2114517.2A GB202114517A GB2596491B GB 2596491 B GB2596491 B GB 2596491B GB 202114517 A GB202114517 A GB 202114517A GB 2596491 B GB2596491 B GB 2596491B
Authority
GB
United Kingdom
Prior art keywords
fraxin
preventing
composition
active ingredients
attention deficit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2114517.2A
Other versions
GB202114517D0 (en
GB2596491A (en
Inventor
Ah Ha Seon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB2114517.2A priority Critical patent/GB2596491B/en
Priority claimed from GB2109624.3A external-priority patent/GB2596927B/en
Publication of GB202114517D0 publication Critical patent/GB202114517D0/en
Publication of GB2596491A publication Critical patent/GB2596491A/en
Application granted granted Critical
Publication of GB2596491B publication Critical patent/GB2596491B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Plant Substances (AREA)
GB2114517.2A 2018-12-18 2018-12-18 Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients Active GB2596491B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2114517.2A GB2596491B (en) 2018-12-18 2018-12-18 Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2109624.3A GB2596927B (en) 2018-12-18 2018-12-18 Composition for preventing or treating dementia and improving cognitive ability
GB2114517.2A GB2596491B (en) 2018-12-18 2018-12-18 Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients

Publications (3)

Publication Number Publication Date
GB202114517D0 GB202114517D0 (en) 2021-11-24
GB2596491A GB2596491A (en) 2021-12-29
GB2596491B true GB2596491B (en) 2022-06-29

Family

ID=78595557

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2114517.2A Active GB2596491B (en) 2018-12-18 2018-12-18 Composition for preventing or treating attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients

Country Status (1)

Country Link
GB (1) GB2596491B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049281A2 (en) * 1999-12-30 2001-07-12 Proteotech, Inc. POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES
KR20110110638A (en) * 2010-04-01 2011-10-07 김현기 Composition for improving recognition comprising galla rhois extract
WO2019109300A1 (en) * 2017-12-07 2019-06-13 Guochuan Emil Tsai Improved enrichment methods for preparing tannic acid compositions
WO2019225983A1 (en) * 2018-05-25 2019-11-28 한국 한의학 연구원 Composition for preventing, ameliorating, or treating depression and anxiety disorders, comprising fraxin as active ingredient
TWI686192B (en) * 2017-02-13 2020-03-01 心悅生醫股份有限公司 Compositions containing tannic acids and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049281A2 (en) * 1999-12-30 2001-07-12 Proteotech, Inc. POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES
KR20110110638A (en) * 2010-04-01 2011-10-07 김현기 Composition for improving recognition comprising galla rhois extract
TWI686192B (en) * 2017-02-13 2020-03-01 心悅生醫股份有限公司 Compositions containing tannic acids and uses thereof
WO2019109300A1 (en) * 2017-12-07 2019-06-13 Guochuan Emil Tsai Improved enrichment methods for preparing tannic acid compositions
WO2019225983A1 (en) * 2018-05-25 2019-11-28 한국 한의학 연구원 Composition for preventing, ameliorating, or treating depression and anxiety disorders, comprising fraxin as active ingredient

Also Published As

Publication number Publication date
GB202114517D0 (en) 2021-11-24
GB2596491A (en) 2021-12-29

Similar Documents

Publication Publication Date Title
GB2540236B (en) Hair cosmetic composition comprising silicones and surfactants, and cosmetic treatment process
EP3463274C0 (en) Composition comprising an anionic surfactant, an organosilane and polyoxyalkylenated or quaternised amino silicone, and cosmetic treatment process
EP3354257A4 (en) Composition, for improving skin and preventing hair loss, comprising plant extract-derived extracellular vesicles
EP3383224A4 (en) System for determining, dispensing, and mixing blended composition for skin treatment
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
EP3630058A4 (en) Compositions and methods for preventing, slowing, and reversing skin aging
SG10202011357RA (en) Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses
HK1250344A1 (en) Composition for preventing hair loss or promoting hair growth, containing ginseng-derived exosome-like vesicles
EP3636744C0 (en) Lactobacillus curvatus wikim55 having activity of promoting hair growth, and composition containing same.
MX2017011309A (en) Hair conditioning compositions with microcapsules.
EP3199174A4 (en) Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof
EP3442497B8 (en) Active combinations, compositions and methods for enhancing hair growth
PL3040078T3 (en) Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent
HK1245631A1 (en) Hydroalcoholic extract of schinus molle, cosmetic compositions comprising the same and cosmetic uses thereof
EP3695827A4 (en) Antibacterial composition, and cosmetic containing said antibacterial composition
EP3295946A4 (en) Composition, containing lithospermi radix extract as active ingredient, for preventing, alleviating, or treating peripheral neuropathy
MX2022012748A (en) Biocide composition and method.
SG10202007780YA (en) Tin-containing dopant compositions, systems and methods for use in ion implantation systems
EP3675874A4 (en) Pharmaceuticals composition for treating keloid and uses thereof
EP3662891C0 (en) Composition for preventing hair loss or promoting hair growth
IL268224A (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients
HK1254449A1 (en) Hair restoration and/or hair growth promoting composition containing soyasaponin
MX2017013819A (en) Cosmetic method and therapeutic use for fat reduction.
EP3461486A4 (en) Pharmaceutical composition for preventing or treating dementia and improving cognitive function, comprising glasswort extract
EP3900732C0 (en) Composition for improving cognitive ability and preventing or treating dementia and attention deficit hyperactivity disorder, comprising galla rhois extract and fraxin as active ingredients